{"id":"ipratropium","rwe":[{"pmid":"41837861","year":"2026","title":"The usefulness of the new SOBIstat-F(®) device in children with severe acute asthma attacks in the emergency department: a randomized clinical trial.","finding":"","journal":"The Journal of asthma : official journal of the Association for the Care of Asthma","studyType":"Clinical Study"},{"pmid":"41822328","year":"2026","title":"Pulmonary infection by Nocardia saintgeorgesii mimicking lung cancer with concurrent pulmonary embolism in an immunocompetent host: a case highlighting the diagnostic role of mNGS.","finding":"","journal":"Frontiers in cellular and infection microbiology","studyType":"Clinical Study"},{"pmid":"41762556","year":"2026","title":"A rare case of lung hernia associated with rib fractures and tension pneumothorax post cardiopulmonary resuscitation.","finding":"","journal":"The American journal of emergency medicine","studyType":"Clinical Study"},{"pmid":"41760017","year":"2026","title":"A case report of combined oxidative phosphorylation deficiency 35 (COXPD35) in Palestine caused by novel compound heterozygous TRIT1 variants.","finding":"","journal":"Medicine","studyType":"Clinical Study"},{"pmid":"41714644","year":"2026","title":"Evaluation of artificial intelligence identified ipratropium bromide for the treatment of coronavirus disease 2019.","finding":"","journal":"Scientific reports","studyType":"Clinical Study"}],"_fda":{"id":"c8dbb0db-5c00-4205-a765-d664117c4398","set_id":"05c56190-e346-4674-a4f8-049ce632ce2d","openfda":{"unii":["J697UZ2A9J"],"route":["NASAL"],"rxcui":["1797833"],"spl_id":["c8dbb0db-5c00-4205-a765-d664117c4398"],"brand_name":["Ipratropium Bromide"],"spl_set_id":["05c56190-e346-4674-a4f8-049ce632ce2d"],"package_ndc":["0054-0045-44"],"product_ndc":["0054-0045"],"generic_name":["IPRATROPIUM BROMIDE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["IPRATROPIUM BROMIDE"],"manufacturer_name":["Hikma Pharmaceuticals USA Inc."],"application_number":["ANDA076664"],"is_original_packager":[true]},"version":"13","effective_time":"20220701","information_for_patients":["PATIENT’S INSTRUCTIONS FOR USE Ipratropium Bromide Nasal Solution, 0.03% Nasal Spray, 21mcg/spray Read complete instructions carefully before using. In order to ensure proper dosing, do not attempt to change the size of the spray opening. Ipratropium bromide nasal solution, 0.03% is indicated for the symptomatic relief of rhinorrhea (runny nose) associated with allergic and nonallergic perennial rhinitis in adults and children age 6 years and older. Ipratropium bromide nasal solution, 0.03% does not relieve nasal congestion, sneezing, or postnasal drip associated with allergic or nonallergic perennial rhinitis. Read complete instructions carefully and use only as directed. To Use: 1. Remove the clear plastic dust cap and the green safety clip from the nasal spray pump ( Figure 1 ). The safety clip prevents the accidental discharge of the spray in your pocket or purse. Figure 1 Figure 1 2. The nasal spray pump must be primed before ipratropium bromide nasal solution, 0.03% is used for the first time. To prime the pump, hold the bottle with your thumb at the base and your index and middle fingers on the white shoulder area. Make sure the bottle points upright and away from your eyes. Press your thumb firmly and quickly against the bottle seven times ( Figure 2 ). The pump is now primed and can be used. Your pump should not have to be reprimed unless you have not used the medication for more than 24 hours; repriming the pump will only require two sprays. If you have not used your nasal spray for more than seven days, repriming the pump will require seven sprays. Figure 2 Figure 2 3. Before using ipratropium bromide nasal solution, 0.03%, blow your nose gently to clear your nostrils if necessary. 4. Close one nostril by gently placing your finger against the side of your nose, tilt your head slightly forward and, keeping the bottle upright, insert the nasal tip into the other nostril ( Figure 3 ). Point the tip toward the back and outer side of the nose. Figure 3 Figure 3 5. Press firmly and quickly upwards with the thumb at the base while holding the white shoulder portion of the pump between your index and middle fingers. Following each spray, sniff deeply and breathe out through your mouth. 6. After spraying the nostril and removing the unit, tilt your head backwards for a few seconds to let the spray spread over the back of the nose. 7. Repeat steps 4 through 6 in the same nostril. 8. Repeat steps 4 through 7 in the other nostril (i.e., two sprays per nostril). 9. Replace the clear plastic dust cap and safety clip. 10. At some time before the medication is completely used up, you should consult your physician or pharmacist to determine whether a refill is needed. You should not take extra doses or stop using ipratropium bromide nasal solution, 0.03% without consulting your physician. To Clean: If the nasal tip becomes clogged, remove the clear plastic dust cap and safety clip. Hold the nasal tip under running, warm tap water ( Figure 4 ) for about a minute. Dry the nasal tip, reprime the nasal spray pump (step 2 above), and replace the plastic dust cap and safety clip. Figure 4 Figure 4 Caution: Ipratropium bromide nasal solution, 0.03% is intended to relieve your rhinorrhea (runny nose) with regular use. It is therefore important that you use ipratropium bromide nasal solution, 0.03% as prescribed by your physician. For most patients, some improvement in runny nose is usually apparent during the first full day of treatment with ipratropium bromide nasal solution, 0.03% Some patients may require up to two weeks of treatment to obtain maximum benefit. Do not spray ipratropium bromide nasal solution, 0.03% in your eyes. Should this occur, immediately flush your eye with cool tap water for several minutes. If you accidentally spray ipratropium bromide nasal solution, 0.03% in your eyes, you may experience a temporary blurring of vision, visual halos or colored images in association with red eyes from conjunctival and corneal congestion, development or worsening of narrow-angle glaucoma, pupil dilation, or acute eye pain/discomfort, and increased sensitivity to light, which may last a few hours. Should acute eye pain or blurred vision occur, contact your doctor. Should you experience excessive nasal dryness or episodes of nasal bleeding contact your doctor. If you have glaucoma or difficulty urinating due to an enlargement of the prostate, be sure to tell your physician prior to using ipratropium bromide nasal solution, 0.03% If you are pregnant or you are breast feeding your baby, be sure to tell your physician prior to using ipratropium bromide nasal solution, 0.03% Storage Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Avoid freezing. Keep out of reach of children. Address medical inquiries to Hikma Pharmaceuticals USA Inc. at 1-800-962-8364. Distributed by: Hikma Pharmaceuticals USA Inc. Berkeley Heights, NJ 07922 C50000619/01 Revised July 2022 figure-1.jpg figure-2.jpg figure-3.jpg figure-4.jpg"],"spl_unclassified_section":["ATTENTION PHARMACISTS: Detach “Patient’s Instructions for Use” from package insert and dispense with product.","Rx only","DESCRIPTION The active ingredient in Ipratropium Bromide Nasal Solution is ipratropium bromide (as the monohydrate). It is an anticholinergic agent chemically described as 8-azoniabicyclo (3.2.1) octane, 3-(3-hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-, bromide monohydrate (3-endo, 8-syn)-: a synthetic quaternary ammonium compound, chemically related to atropine. The structural formula is: ipratropium bromide C 20 H 30 BrNO 3 • H 2 O Mol. Wt. 430.4 ipratropium bromide C 20 H 30 BrNO 3 • H 2 O Mol. Wt. 430.4 Ipratropium bromide is a white to off-white crystalline substance, freely soluble in water and methanol, sparingly soluble in ethanol, and insoluble in non-polar media. In aqueous solution, it exists in an ionized state as a quaternary ammonium compound. Ipratropium Bromide Nasal Solution, 0.03% is a metered-dose, manual pump spray unit which delivers 21 mcg (70 mcL) ipratropium bromide per spray on an anhydrous basis in an isotonic, aqueous solution with pH adjusted to 4.7 with hydrochloric acid and/or sodium hydroxide (if needed). It also contains benzalkonium chloride, edetate disodium, purified water and sodium chloride. Each bottle contains 345 metered sprays. structural formula","CLINICAL PHARMACOLOGY Mechanism of Action Ipratropium bromide is an anticholinergic (parasympatholytic) agent which, based on animal studies, appears to inhibit vagally-mediated reflexes by antagonizing the action of acetylcholine, the transmitter agent released at the neuromuscular junctions in the lung. In humans, ipratropium bromide has anti-secretory properties and, when applied locally, inhibits secretions from the serous and seromucous glands lining the nasal mucosa. Ipratropium bromide is a quaternary amine that minimally crosses the nasal and gastrointestinal membrane and the blood-brain barrier, resulting in a reduction of the systemic anticholinergic effects (e.g., neurologic, ophthalmic, cardiovascular, and gastrointestinal effects) that are seen with tertiary anticholinergic amines. Pharmacokinetics Absorption Ipratropium bromide is poorly absorbed into the systemic circulation following oral administration (2 to 3%). Less than 20% of an 84 mcg per nostril dose was absorbed from the nasal mucosa of normal volunteers, induced-cold patients, or perennial rhinitis patients. Distribution Ipratropium bromide is minimally bound (0 to 9% in vitro ) to plasma albumin and α 1 -acid glycoprotein. Its blood/plasma concentration ratio was estimated to be about 0.89. Studies in rats have shown that ipratropium bromide does not penetrate the blood-brain barrier. Metabolism Ipratropium bromide is partially metabolized to ester hydrolysis products, tropic acid and tropane. These metabolites appear to be inactive based on in vitro receptor affinity studies using rat brain tissue homogenates. Elimination After intravenous administration of 2 mg ipratropium bromide to 10 healthy volunteers, the terminal half-life of ipratropium was approximately 1.6 hours. The total body clearance and renal clearance were estimated to be 2,505 and 1,019 ml/min, respectively. The amount of the total dose excreted unchanged in the urine (Ae) within 24 hours was approximately one-half of the administered dose. Pediatrics Following administration of 42 mcg of ipratropium bromide per nostril two or three times a day in perennial rhinitis patients 6 to 18 years old, the mean amounts of the total dose excreted unchanged in the urine (8.6 to 11.1%) were higher than those reported in adult volunteers or adult perennial rhinitis patients (3.7 to 5.6%). Plasma ipratropium concentrations were relatively low (ranging from undetectable up to 0.49 ng/ml). No correlation of the amount of the total dose excreted unchanged in the urine (Ae) with age or gender was observed in the pediatric population. Special Populations Gender does not appear to influence the absorption or excretion of nasally administered ipratropium bromide. The pharmacokinetics of ipratropium bromide have not been studied in patients with hepatic or renal insufficiency or in the elderly. Drug-Drug Interaction No specific pharmacokinetic studies were conducted to evaluate potential drug-drug interactions. Pharmacodynamics In two single-dose trials (n=17), doses up to 336 mcg of ipratropium bromide did not significantly affect pupillary diameter, heart rate, or systolic/diastolic blood pressure. Similarly, in patients with induced-colds, ipratropium bromide 0.06% (84 mcg/nostril four times a day), had no significant effects on pupillary diameter, heart rate or systolic/diastolic blood pressure. Two nasal provocation trials in perennial rhinitis patients (n=44) using ipratropium bromide nasal spray showed a dose dependent increase in inhibition of methacholine induced nasal secretion with an onset of action within 15 minutes (time of first observation). Controlled clinical trials demonstrated that intranasal fluorocarbon-propelled ipratropium bromide does not alter physiologic nasal functions (e.g., sense of smell, ciliary beat frequency, mucociliary clearance, or the air conditioning capacity of the nose). Clinical Trials The clinical trials for ipratropium bromide 0.03% were conducted in patients with nonallergic perennial rhinitis (NAPR) and in patients with allergic perennial rhinitis (APR). APR patients were those who experienced symptoms of nasal hypersecretion and nasal congestion or sneezing when exposed to specific perennial allergens (e.g., dust mites, molds) and were skin test positive to these allergens. NAPR patients were those who experienced symptoms of nasal hypersecretion and nasal congestion or sneezing throughout the year, but were skin test negative to common perennial allergens. In four controlled, four- and eight-week comparisons of ipratropium bromide 0.03% (42 mcg per nostril, two or three times daily) with its vehicle, in patients with allergic or nonallergic perennial rhinitis, there was a statistically significant decrease in the severity and duration of rhinorrhea in the ipratropium bromide group throughout the entire study period. An effect was seen as early as the first day of therapy. There was no effect of ipratropium bromide 0.03% on degree of nasal congestion, sneezing, or postnasal drip. The response to ipratropium bromide 0.03% did not appear to be affected by the type of perennial rhinitis (NAPR or APR), age, or gender. No controlled clinical trials directly compared the efficacy of BID versus TID treatment.","INDICATIONS AND USAGE Ipratropium bromide nasal solution 0.03% is indicated for the symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis in adults and children age 6 years and older. Ipratropium bromide 0.03% does not relieve nasal congestion, sneezing, or postnasal drip associated with allergic or nonallergic perennial rhinitis.","CONTRAINDICATIONS Ipratropium bromide nasal solution 0.03% is contraindicated in patients with a history of hypersensitivity to atropine or its derivatives, or to any of the other ingredients.","WARNINGS Immediate hypersensitivity reactions may occur after administration of ipratropium bromide, as demonstrated by urticaria, angioedema, rash, bronchospasm, anaphylaxis, and oropharyngeal edema. If such a reaction occurs, therapy with ipratropium bromide should be stopped at once and alternative treatment should be considered.","PRECAUTIONS General 1. Effects Seen with Anticholinergic Drugs : Ipratropium bromide should be used with caution in patients with narrow-angle glaucoma, prostatic hyperplasia, or bladder neck obstruction, particularly if they are receiving an anticholinergic by another route. 2. Use in Hepatic or Renal Disease : Ipratropium bromide has not been studied in patients with hepatic or renal insufficiency. It should be used with caution in those patient populations. Information for Patients Patients should be advised that temporary blurring of vision, precipitation or worsening of narrow-angle glaucoma, mydriasis, increased intraocular pressure, acute eye pain or discomfort, visual halos or colored images in association with red eyes from conjunctival and corneal congestion may result if ipratropium bromide comes into direct contact with eyes. Patients should be instructed to avoid spraying ipratropium bromide in or around their eyes. Patients who experience eye pain, blurred vision, excessive nasal dryness, or episodes of nasal bleeding should be instructed to contact their doctor. To ensure proper dosing, patients should be advised not to alter the size of the nasal spray opening. Patients should be reminded to carefully read and follow the accompanying “Patient’s Instructions for Use” . Since dizziness, accommodation disorder, mydriasis, and blurred vision may occur with use of ipratropium bromide, patients should be cautioned about engaging in activities requiring balance and visual acuity such as driving a car or operating appliances, machinery, etc. Drug Interactions No controlled clinical trials were conducted to investigate potential drug-drug interactions. There is potential for an additive interaction with other concomitantly administered medications with anticholinergic properties, including ipratropium bromide for oral inhalation. Carcinogenesis, Mutagenesis, Impairment of Fertility Two-year oral carcinogenicity studies in rats and mice have revealed no carcinogenic activity at doses up to 6 mg/kg. This dose corresponds in rats and mice to approximately 190 and 95 times the maximum recommended daily intranasal dose in adults, respectively, and approximately 110 and 55 times the maximum recommended daily intranasal dose in children, respectively, on a mg/m 2 basis. Results of various mutagenicity studies (Ames test, mouse dominant lethal test, mouse micronucleus test, and chromosome aberration of bone marrow in Chinese hamsters) were negative. Fertility of male or female rats at oral doses up to 50 mg/kg (approximately 1,600 times the maximum recommended daily intranasal dose in adults on a mg/m 2 basis) was unaffected by ipratropium bromide administration. At an oral dose of 500 mg/kg (approximately 16,000 times the maximum recommended daily intranasal dose in adults on a mg/m 2 basis), ipratropium bromide produced a decrease in the conception rate. Pregnancy Teratogenic Effects Pregnancy Category B There are no adequate and well-controlled studies for ipratropium bromide in pregnant women. Because animal reproduction studies are not always predictive of human response, ipratropium bromide should be used during pregnancy only if clearly needed. Oral reproduction studies were performed at ipratropium doses of 10 mg/kg in mice, 1,000 mg/kg in rats and 125 mg/kg in rabbits. These doses correspond, in each species respectively, to approximately 160, 32,000, and 8,000 times the maximum recommended daily intranasal dose (MRDID) in adults on a mg/m 2 basis. Inhalation reproduction studies were conducted in rats and rabbits at doses of 1.5 and 1.8 mg/kg, respectively, (approximately 50 and 120 times, respectively, the MRDID in adults on a mg/m 2 basis). These studies demonstrated no evidence of teratogenic effects as a result of ipratropium bromide. At oral doses 90 mg/kg and above in rats (approximately 2,900 times the MRDID in adults on a mg/m 2 basis) embryotoxicity was observed as increased resorption. This effect is not considered relevant to human use due to the large doses at which it was observed and the difference in route of administration. Labor and Delivery The effect of ipratropium bromide on labor and delivery is unknown. Nursing Mothers It is known that some ipratropium bromide is systemically absorbed following nasal administration; however the portion which may be excreted in human milk is unknown. Because lipid-insoluble quaternary cations pass into breast milk, caution should be exercised when ipratropium bromide is administered to a nursing mother. Pediatric Use The safety of ipratropium bromide nasal solution, 0.03% at a dose of two sprays (42 mcg) per nostril two or three times daily (total dose 168 to 252 mcg/day) has been demonstrated in 77 pediatric patients 6 to 12 years of age in placebo-controlled, 4-week trials and in 55 pediatric patients in active-controlled, 6 month trials. The effectiveness of ipratropium bromide nasal solution, 0.03% for the treatment of rhinorrhea associated with allergic and nonallergic perennial rhinitis in this pediatric age group is based on an extrapolation of the demonstrated efficacy of ipratropium bromide nasal solution, 0.03% in adults with these conditions and the likelihood that the disease course, pathophysiology, and the drug’s effects are substantially similar to that of the adults. The recommended dose for the pediatric population is based on within and cross-study comparisons of the efficacy of ipratropium bromide nasal solution, 0.03% in adults and pediatric patients and on its safety profile in both adults and pediatric patients. The safety and effectiveness of ipratropium bromide nasal solution, 0.03% in patients under 6 years of age have not been established.","ADVERSE REACTIONS Adverse reaction information on ipratropium bromide nasal solution, 0.03% in patients with perennial rhinitis was derived from four multicenter, vehicle-controlled clinical trials involving 703 patients (356 patients on ipratropium bromide and 347 patients on vehicle), and a one-year, open-label, follow-up trial. In three of the trials, patients received ipratropium bromide 0.03% three times daily, for eight weeks. In the other trial, ipratropium bromide 0.03% was given to patients two times daily for four weeks. Of the 285 patients who entered the open-label, follow-up trial, 232 were treated for 3 months, 200 for 6 months, and 159 up to one year. The majority (>86%) of patients treated for one year were maintained on 42 mcg per nostril, two or three times daily, of ipratropium bromide 0.03%. Table 1 shows adverse events, and the frequency that these adverse events led to the discontinuation of treatment, reported for patients who received ipratropium bromide 0.03% at the recommended dose of 42 mcg per nostril, or vehicle two or three times daily for four or eight weeks. Only adverse events reported with an incidence of at least 2.0% in the ipratropium bromide group and higher in the ipratropium bromide group than in the vehicle group are shown. Table 1: % of Patients Reporting Events + Ipratropium Bromide Nasal Spray 0.03% (n=356) Vehicle Control (n=347) Incidence % Discontinued % Incidence % Discontinued % Headache 9.8 0.6 9.2 0.0 Upper respiratory tract infection 9.8 1.4 7.2 1.4 Epistaxis 1 9.0 0.3 4.6 0.3 Rhinitis * Nasal dryness 5.1 0.0 0.9 0.3 Nasal irritation 2 2.0 0.0 1.7 0.6 Other nasal symptoms 3 3.1 1.1 1.7 0.3 Pharyngitis 8.1 0.3 4.6 0.0 Nausea 2.2 0.3 0.9 0.0 + This table includes adverse events which occurred at an incidence rate of at least 2.0% in the Ipratropium Bromide group and more frequently in the Ipratropium Bromide group than in the vehicle group. 1 Epistaxis reported by 7.0% of Ipratropium Bromide patients and 2.3% of vehicle patients, blood-tinged mucus by 2.0% of Ipratropium Bromide patients and 2.3% of vehicle patients. 2 Nasal irritation includes reports of nasal itching, nasal burning, nasal irritation, and ulcerative rhinitis. 3 Other nasal symptoms include reports of nasal congestion, increased rhinorrhea, increased rhinitis, posterior nasal drip, sneezing, nasal polyps, and nasal edema. * All events are listed by their WHO term; rhinitis has been presented by descriptive terms for clarification. Ipratropium bromide 0.03% was well tolerated by most patients. The most frequently reported nasal adverse events were transient episodes of nasal dryness or epistaxis. These adverse events were mild or moderate in nature, none was considered serious, none resulted in hospitalization and most resolved spontaneously or following a dose reduction. Treatment for nasal dryness and epistaxis was required infrequently (2% or less) and consisted of local application of pressure or a moisturizing agent (e.g., petroleum jelly or saline nasal spray). Patient discontinuation for epistaxis or nasal dryness was infrequent in both the controlled (0.3% or less) and one-year, open-label (2% or less) trials. There was no evidence of nasal rebound (i.e., a clinically significant increase in rhinorrhea, posterior nasal drip, sneezing or nasal congestion severity compared to baseline) upon discontinuation of double-blind therapy in these trials. Adverse events reported by less than 2% of the patients receiving ipratropium bromide 0.03% during the controlled clinical trials or during the open-label follow-up trial, which are potentially related to Ipratropium Bromide’s local effects or systemic anticholinergic effects include: dry mouth/throat, dizziness, ocular irritation, blurred vision, conjunctivitis, hoarseness, cough, and taste perversion. There were infrequent reports of skin rash in both the controlled and uncontrolled clinical studies. Post-Marketing Experience Allergic type reactions such as skin rash, angioedema, including that of the throat, tongue, lips and face, generalized urticaria (including giant urticaria), laryngospasm, and anaphylactic reactions have been reported with ipratropium bromide 0.03% and for other ipratropium bromide-containing products, with positive rechallenge in some cases. Additional side effects identified from the published literature and/or post-marketing surveillance on the use of ipratropium bromide-containing products (singly or in combination with albuterol), include: urinary retention, prostatic disorders, mydriasis, cases of precipitation or worsening of narrow-angle glaucoma, acute eye pain, wheezing, dryness of the oropharynx, sinusitis, tachycardia, palpitations, pain, edema, gastrointestinal distress (diarrhea, nausea, vomiting), bowel obstruction, constipation, nasal discomfort, throat irritation, hypersensitivity, accommodation disorder, intraocular pressure increased, glaucoma, halo vision, conjunctival hyperaemia, corneal edema, heart rate increased, bronchospasm, pharyngeal edema, gastrointestinal motility disorder, mouth edema, stomatitis, and pruritus. After oral inhalation of ipratropium bromide in patients suffering from COPD/Asthma supraventricular tachycardia and atrial fibrillation have been reported.","OVERDOSAGE Acute overdosage by intranasal administration is unlikely since ipratropium bromide is not well absorbed systemically after intranasal or oral administration. Following administration of a 20 mg oral dose (equivalent to ingesting more than four bottles of ipratropium bromide 0.03%) to 10 male volunteers, no change in heart rate or blood pressure was noted. Following a 2 mg intravenous infusion over 15 minutes to the same 10 male volunteers, plasma ipratropium concentrations of 22 to 45 ng/mL were observed (>100 times the concentrations observed following intranasal administration). Following intravenous infusion these 10 volunteers had a mean increase of heart rate of 50 bpm and less than 20 mmHg change in systolic or diastolic blood pressure at the time of peak ipratropium levels.","DOSAGE AND ADMINISTRATION The recommended dose of ipratropium bromide solution, 0.03% is two sprays (42 mcg) per nostril two or three times daily (total dose 168 to 252 mcg/day) for the symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis in adults and children age 6 years and older. Optimum dosage varies with the response of the individual patient. Initial pump priming requires seven sprays of the pump. If used regularly as recommended, no further priming is required. If not used for more than 24 hours, the pump will require two sprays, or if not used for more than seven days, the pump will require seven sprays to reprime. Avoid spraying into eyes.","HOW SUPPLIED Ipratropium Bromide Nasal Solution, 0.03% is supplied as a clear, colorless solution in a white high density polyethylene (HDPE) bottle fitted with a white and clear metered nasal spray pump, a green safety clip to prevent accidental discharge of the spray, and a clear plastic dust cap. It contains 31.1 g of product formulation, 345 sprays, each delivering 21 mcg (70 mcL) of ipratropium per spray, or 28 days of therapy at the maximum recommended dose (two sprays per nostril three times a day). Ipratropium Bromide Nasal Solution, 0.03% Nasal Spray, 21 mcg/spray NDC 0054-0045-44: Bottle of 30 mL (345 metered sprays) Storage Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Avoid freezing. Keep out of reach of children. Do not spray in the eyes. Address medical inquiries to Hikma Pharmaceuticals USA Inc. at 1-800-962-8364. Patients should be reminded to read and follow the accompanying “Patient’s Instructions for Use” , which should be dispensed with the product. Distributed by: Hikma Pharmaceuticals USA Inc. Berkeley Heights, NJ 07922 C50000619/01 Revised July 2022"],"spl_product_data_elements":["Ipratropium Bromide Ipratropium Bromide BENZALKONIUM CHLORIDE EDETATE CALCIUM DISODIUM HYDROCHLORIC ACID WATER SODIUM CHLORIDE SODIUM HYDROXIDE HYDROXYETHYL CELLULOSE (140 MPA.S AT 5%) IPRATROPIUM BROMIDE IPRATROPIUM IPRATROPIUM BROMIDE ANHYDROUS"],"spl_unclassified_section_table":["
Table 1: % of Patients Reporting Events+
Ipratropium Bromide Nasal Spray 0.03%(n=356)Vehicle Control(n=347)
Incidence%Discontinued%Incidence%Discontinued%
Headache9.80.69.20.0
Upper respiratory tract infection9.81.47.21.4
Epistaxis19.00.34.60.3
Rhinitis*
Nasal dryness5.10.00.90.3
Nasal irritation22.00.01.70.6
Other nasal symptoms33.11.11.70.3
Pharyngitis8.10.34.60.0
Nausea2.20.30.90.0
+ This table includes adverse events which occurred at an incidence rate of at least 2.0% in the Ipratropium Bromide group and more frequently in the Ipratropium Bromide group than in the vehicle group.
1 Epistaxis reported by 7.0% of Ipratropium Bromide patients and 2.3% of vehicle patients, blood-tinged mucus by 2.0% of Ipratropium Bromide patients and 2.3% of vehicle patients.
2 Nasal irritation includes reports of nasal itching, nasal burning, nasal irritation, and ulcerative rhinitis.
3 Other nasal symptoms include reports of nasal congestion, increased rhinorrhea, increased rhinitis, posterior nasal drip, sneezing, nasal polyps, and nasal edema.
* All events are listed by their WHO term; rhinitis has been presented by descriptive terms for clarification.
"],"package_label_principal_display_panel":["PACKAGE/LABEL PRINCIPAL DISPLAY PANEL NDC 0054- 0045 -44 30 mL (345 metered sprays) Ipratropium Bromide Nasal Solution / Nasal Spray 0.03% 21 mcg/spray Rx only 0.03% bottle label","PACKAGE/LABEL PRINCIPAL DISPLAY PANEL NDC 0054- 0045 -44 30 mL (345 metered sprays) Ipratropium Bromide Nasal Solution 0.03% Nasal Spray 21 mcg/spray Rx only 0.03% folding carton"]},"tags":[{"label":"Anticholinergic","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Muscarinic acetylcholine receptor M1","category":"target"},{"label":"CHRM1","category":"gene"},{"label":"CHRM3","category":"gene"},{"label":"CHRM4","category":"gene"},{"label":"R01AX03","category":"atc"},{"label":"Respiratory (Inhalation)","category":"route"},{"label":"Nasal","category":"route"},{"label":"Aerosol","category":"form"},{"label":"Inhalant","category":"form"},{"label":"Solution","category":"form"},{"label":"Spray","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Established","category":"status"},{"label":"Allergic rhinitis","category":"indication"},{"label":"Bronchitis","category":"indication"},{"label":"Bronchospasm","category":"indication"},{"label":"Chronic Obstructive Pulmonary Disease with Bronchospasms","category":"indication"},{"label":"Chronic obstructive lung disease","category":"indication"},{"label":"Nasal discharge","category":"indication"},{"label":"Approved 1980s","category":"decade"},{"label":"Anti-Asthmatic Agents","category":"pharmacology"},{"label":"Bronchodilator Agents","category":"pharmacology"},{"label":"Cholinergic Agents","category":"pharmacology"},{"label":"Cholinergic Antagonists","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"},{"label":"Peripheral Nervous System Agents","category":"pharmacology"},{"label":"Respiratory System Agents","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"6461 reports"},{"date":"","signal":"ASTHMA","source":"FDA FAERS","actionTaken":"4060 reports"},{"date":"","signal":"PNEUMONIA","source":"FDA FAERS","actionTaken":"3282 reports"},{"date":"","signal":"COUGH","source":"FDA FAERS","actionTaken":"3136 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"2875 reports"},{"date":"","signal":"WHEEZING","source":"FDA FAERS","actionTaken":"2691 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"2367 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"2096 reports"},{"date":"","signal":"CHRONIC OBSTRUCTIVE PULMONARY DISEASE","source":"FDA FAERS","actionTaken":"1917 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"1898 reports"}],"commonSideEffects":[{"effect":"Bronchitis","drugRate":"","severity":"common","organSystem":""},{"effect":"COPD exacerbation","drugRate":"","severity":"common","organSystem":""},{"effect":"Dyspnea","drugRate":"","severity":"common","organSystem":""},{"effect":"Headache","drugRate":"","severity":"common","organSystem":""},{"effect":"Dry mouth","drugRate":"1.6%","severity":"common","organSystem":""},{"effect":"Taste perversion (bitter taste)","drugRate":"0.9%","severity":"common","organSystem":""},{"effect":"Cough","drugRate":"","severity":"common","organSystem":""},{"effect":"Rhinitis","drugRate":"","severity":"common","organSystem":""},{"effect":"Upper respiratory infection","drugRate":"","severity":"common","organSystem":""},{"effect":"Throat irritation","drugRate":"","severity":"common","organSystem":""},{"effect":"Stomatitis","drugRate":"","severity":"common","organSystem":""},{"effect":"Mouth edema","drugRate":"","severity":"common","organSystem":""},{"effect":"Vision blurred","drugRate":"","severity":"common","organSystem":""}],"contraindications":["Angle-closure glaucoma","Benign prostatic hyperplasia","Bladder outflow obstruction","Chronic myocardial ischemia","Conduction disorder of the heart","Congenital long QT syndrome","Diabetes mellitus","Hypertensive disorder","Hyperthyroidism","Hypokalemia","Ketoacidosis","Metabolic acidosis","Myocardial ischemia","Ocular hypertension","Paradoxical bronchospasm","Prolonged QT interval","Retention of urine","Seizure disorder"],"specialPopulations":{"Pregnancy":"Ipratropium is negligibly absorbed systemically following oral inhalation; therefore, maternal use is not expected to result in fetal exposure to the drug. There is limited experience with ipratropium bromide use in pregnant women. Published literature, including cohort studies, case control studies and case series, over several decades have not identified drug associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Based on animal reproduction studies, no evidence of structural alterations was observed when ipratropium bromide was administered to pregnant mice, rats and rabbits during organogenesis at doses up to approximately 200, 40,000, and 10,000 times, respectively, the maximum recommended human daily inhalation dose (MRHDID) in adults. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have background risk of birth defect, loss or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. There are no adequate and well-controlled studies for Ipratropium Bromide Nasal Solution 0.06% (Nasal Spray) in pregnant women. Because animal reproduction studies are not always predictive of human response, Ipratropium Bromide Nasal Solution 0.06% (Nasal Spray) should be used during pregnancy only if clearly needed.","Geriatric use":"In the pivotal 12-week study, both ATROVENT HFA Inhalation Aerosol and Atrovent(R) (ipratropium bromide) Inhalation Aerosol CFC formulations were equally effective in patients over 65 years of age and under 65 years of age. Of the total number of subjects in clinical studies of ATROVENT HFA Inhalation Aerosol, 57% were >= 65 years of age. No overall differences in safety or effectiveness were observed between these subjects and younger subjects.","Paediatric use":"The safety of ipratropium bromide nasal solution 0.06% (Nasal Spray) at dose of two sprays (84 mcg) per nostril three times day (total dose 504 mcg/day) for two to four days has been demonstrated in two clinical trials involving 362 pediatric patients 5-11 years of age with naturally acquired common colds. In this pediatric population ipratropium bromide nasal solution 0.06% (Nasal Spray) had an adverse event profile similar to that observed in adolescent and adult patients."},"seriousAdverseEvents":[{"effect":"Hypersensitivity reactions including anaphylaxis","drugRate":"","severity":"serious"},{"effect":"Paradoxical bronchospasm","drugRate":"","severity":"serious"},{"effect":"Narrow-angle glaucoma precipitation or worsening","drugRate":"","severity":"serious"},{"effect":"Glaucoma","drugRate":"","severity":"serious"},{"effect":"Urinary retention","drugRate":"","severity":"serious"},{"effect":"Bronchospasm","drugRate":"","severity":"serious"},{"effect":"Angioedema","drugRate":"","severity":"serious"},{"effect":"Laryngospasm","drugRate":"","severity":"serious"},{"effect":"Supraventricular tachycardia","drugRate":"","severity":"serious"},{"effect":"Atrial fibrillation","drugRate":"","severity":"serious"}]},"trials":[],"aliases":[],"patents":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$0.6117/ML","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$220","description":"IPRATROPIUM 0.03% SPRAY","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=IPRATROPIUM","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:44:09.329933+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Ipratropium","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T01:44:17.088831+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:44:15.369946+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T01:44:08.451683+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=IPRATROPIUM","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:44:15.835882+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:44:05.953222+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:44:05.953250+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T01:44:17.531785+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1621597/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:44:16.650513+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA076664","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:44:05.953254+00:00"}},"allNames":"atrovent","offLabel":[],"synonyms":["ipratropium","ipratropium bromide","ipratropium bromide hydrate","ipratropium bromide monohydrate"],"timeline":[{"date":"1986-12-29","type":"positive","source":"DrugCentral","milestone":"FDA approval"},{"date":"1993-09-29","type":"positive","source":"FDA Orange Book","milestone":"Atrovent approved — 0.02% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**"},{"date":"1995-10-20","type":"positive","source":"FDA Orange Book","milestone":"Atrovent approved — 0.021MG/SPRAY **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**"},{"date":"2003-04-18","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 10 manufacturers approved"},{"date":"2004-11-27","type":"positive","source":"FDA Orange Book","milestone":"Atrovent Hfa approved — 0.021MG/INH"}],"aiSummary":"Atrovent (IPRATROPIUM) is a small molecule anticholinergic medication developed by Boehringer Ingelheim, targeting the muscarinic acetylcholine receptor M1. It was FDA-approved in 1986 for various respiratory conditions, including allergic rhinitis, bronchitis, and chronic obstructive pulmonary disease. As an off-patent medication, Atrovent is available from multiple generic manufacturers. Key safety considerations include its potential to cause dry mouth, blurred vision, and urinary retention. Atrovent's commercial status allows for generic competition, making it a widely accessible treatment option.","approvals":[{"date":"1986-12-29","orphan":false,"company":"","regulator":"FDA"}],"brandName":"Atrovent","ecosystem":[{"indication":"Allergic rhinitis","otherDrugs":[{"name":"acrivastine","slug":"acrivastine","company":"Auxilium Pharms Inc"},{"name":"alimemazine","slug":"alimemazine","company":"Allergan Herbert"},{"name":"antazoline","slug":"antazoline","company":"Novartis"},{"name":"astemizole","slug":"astemizole","company":""}],"globalPrevalence":null},{"indication":"Bronchitis","otherDrugs":[{"name":"acetylcysteine","slug":"acetylcysteine","company":"Apothecon"},{"name":"amphotericin B","slug":"amphotericin-b","company":"Apothecon"},{"name":"bitolterol","slug":"bitolterol","company":"Sanofi Aventis Us"},{"name":"cefixime","slug":"cefixime","company":""}],"globalPrevalence":null},{"indication":"Bronchospasm","otherDrugs":[{"name":"diprophylline","slug":"diprophylline","company":""},{"name":"ephedrine","slug":"ephedrine","company":""},{"name":"levosalbutamol","slug":"levosalbutamol","company":"Oak Pharms Inc"},{"name":"salbutamol","slug":"salbutamol","company":"Schering"}],"globalPrevalence":null},{"indication":"Chronic Obstructive Pulmonary Disease with Bronchospasms","otherDrugs":[{"name":"salbutamol","slug":"salbutamol","company":"Schering"},{"name":"terbutaline","slug":"terbutaline","company":""},{"name":"theophylline","slug":"theophylline","company":"Gd Searle Llc"},{"name":"tiotropium bromide","slug":"tiotropium-bromide","company":"Boehringer Ingelheim"}],"globalPrevalence":392000000},{"indication":"Chronic obstructive lung disease","otherDrugs":[{"name":"aclidinium bromide","slug":"aclidinium-bromide","company":"Astrazeneca Pharms"},{"name":"arformoterol","slug":"arformoterol","company":"Sunovion"},{"name":"fluticasone furoate","slug":"fluticasone-furoate","company":"Glaxosmithkline"},{"name":"glycopyrronium bromide","slug":"glycopyrronium-bromide","company":"Shionogi Inc"}],"globalPrevalence":391900000},{"indication":"Nasal discharge","otherDrugs":[{"name":"acrivastine","slug":"acrivastine","company":"Auxilium Pharms Inc"},{"name":"alimemazine","slug":"alimemazine","company":"Allergan Herbert"},{"name":"ammonium chloride","slug":"ammonium-chloride","company":"B Braun"},{"name":"antazoline","slug":"antazoline","company":"Novartis"}],"globalPrevalence":30000000},{"indication":"Pulmonary emphysema","otherDrugs":[{"name":"arformoterol","slug":"arformoterol","company":"Sunovion"},{"name":"bitolterol","slug":"bitolterol","company":"Sanofi Aventis Us"},{"name":"diprophylline","slug":"diprophylline","company":""},{"name":"epinephrine","slug":"epinephrine","company":""}],"globalPrevalence":null}],"mechanism":{"target":"Muscarinic acetylcholine receptor M1","novelty":"Follow-on","targets":[{"gene":"CHRM1","source":"DrugCentral","target":"Muscarinic acetylcholine receptor M1","protein":"Muscarinic acetylcholine receptor M1"},{"gene":"CHRM3","source":"DrugCentral","target":"Muscarinic acetylcholine receptor M3","protein":"Muscarinic acetylcholine receptor M3"},{"gene":"CHRM4","source":"DrugCentral","target":"Muscarinic acetylcholine receptor M4","protein":"Muscarinic acetylcholine receptor M4"},{"gene":"CHRM2","source":"DrugCentral","target":"Muscarinic acetylcholine receptor M2","protein":"Muscarinic acetylcholine receptor M2"},{"gene":"CHRM5","source":"DrugCentral","target":"Muscarinic acetylcholine receptor M5","protein":"Muscarinic acetylcholine receptor M5"},{"gene":"SLC22A2","source":"DrugCentral","target":"Solute carrier family 22 member 2","protein":"Solute carrier family 22 member 2"}],"moaClass":"Cholinergic Antagonists","modality":"Small Molecule","drugClass":"Anticholinergic","explanation":"","oneSentence":"","technicalDetail":"Atrovent (IPRATROPIUM) is a selective M1 muscarinic receptor antagonist that competitively inhibits the action of acetylcholine, resulting in bronchodilation and reduced airway resistance."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Ipratropium_bromide","title":"Ipratropium bromide","extract":"Ipratropium bromide, sold under the trade name Atrovent among others, is a type of anticholinergic medication which is applied by different routes: inhaler, nebulizer, or nasal spray, for different reasons."},"commercial":{"launchDate":"1986","_launchSource":"DrugCentral (FDA 1986-12-29, )"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1475","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=IPRATROPIUM","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=IPRATROPIUM","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Ipratropium_bromide","fields":["history","overview"],"source":"Wikipedia"},{"id":5,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T12:09:12.249184","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:44:18.579608+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"retinol","drugSlug":"retinol","fdaApproval":"1953-02-20","relationship":"same-class"},{"drugName":"mupirocin","drugSlug":"mupirocin","fdaApproval":"1987-12-31","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"hyaluronic acid","drugSlug":"hyaluronic-acid","fdaApproval":"","relationship":"same-class"}],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"genericName":"ipratropium","indications":{"approved":[{"name":"Allergic rhinitis","source":"DrugCentral","snomedId":61582004,"regulator":"FDA"},{"name":"Bronchitis","source":"DrugCentral","snomedId":32398004,"regulator":"FDA","eligibility":""},{"name":"Bronchospasm","source":"DrugCentral","snomedId":4386001,"regulator":"FDA","eligibility":""},{"name":"Chronic Obstructive Pulmonary Disease with Bronchospasms","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"","usPrevalence":16000000,"globalPrevalence":392000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2023"},{"name":"Chronic obstructive lung disease","source":"DrugCentral","snomedId":13645005,"regulator":"FDA","eligibility":"","usPrevalence":null,"globalPrevalence":391900000,"prevalenceMethod":"curated","prevalenceSource":"Lancet Respir Med, 2019 (PMID:35279265)"},{"name":"Nasal discharge","source":"DrugCentral","snomedId":64531003,"regulator":"FDA","eligibility":"","usPrevalence":null,"globalPrevalence":30000000,"prevalenceMethod":"curated","prevalenceSource":"Influenza Other Respir Viruses, 2023 (PMID:36824394)"},{"name":"Pulmonary emphysema","source":"DrugCentral","snomedId":87433001,"regulator":"FDA","eligibility":""}],"offLabel":[{"name":"Asthma","source":"DrugCentral","drugName":"IPRATROPIUM","evidenceCount":1189,"evidenceLevel":"strong"},{"name":"Asthma-chronic obstructive pulmonary disease overlap syndrome","source":"DrugCentral","drugName":"IPRATROPIUM","evidenceCount":2,"evidenceLevel":"emerging"}],"pipeline":[]},"currentOwner":"Boehringer Ingelheim","drugCategory":"established","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"retinol","brandName":"retinol","genericName":"retinol","approvalYear":"1953","relationship":"same-class"},{"drugId":"mupirocin","brandName":"mupirocin","genericName":"mupirocin","approvalYear":"1987","relationship":"same-class"},{"drugId":"hyaluronic-acid","brandName":"hyaluronic acid","genericName":"hyaluronic acid","approvalYear":"","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07394036","phase":"PHASE2","title":"Effect of Ipratropium Bromide on EILO","status":"NOT_YET_RECRUITING","sponsor":"Cook Children's Health Care System","startDate":"2026-03-16","conditions":["Exercise-Induced Laryngeal Obstruction","Dyspnea During Activity"],"enrollment":50,"completionDate":"2029-03-30"},{"nctId":"NCT06785272","phase":"PHASE3","title":"Magnesium Trial in Acute Asthma in Emergency Department","status":"RECRUITING","sponsor":"Suzanne Schuh","startDate":"2025-10-08","conditions":["Asthma"],"enrollment":192,"completionDate":"2027-10"},{"nctId":"NCT05480566","phase":"NA","title":"Functional Strength Training and Neuromuscular Electrical Stimulation in Severe Acute Exacerbations of COPD","status":"TERMINATED","sponsor":"Hasselt University","startDate":"2022-06-01","conditions":["Acute Exacerbation of Chronic Obstructive Pulmonary Disease","Acute Exacerbation of COPD"],"enrollment":35,"completionDate":"2023-12-01"},{"nctId":"NCT04315558","phase":"PHASE2","title":"Revefenacin in Acute Respiratory Insufficiency in COPD","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2020-11-01","conditions":["COPD","Acute Respiratory Failure"],"enrollment":21,"completionDate":"2025-01-01"},{"nctId":"NCT07112456","phase":"PHASE2","title":"Nebulized Ketamine Plus Standard Care vs. Standard Care Alone in Moderate to Severe Asthma Exacerbations","status":"NOT_YET_RECRUITING","sponsor":"Oman Medical Speciality Board","startDate":"2026-09-01","conditions":["Asthma Acute","Asthma Attack","Asthma Exacerbations"],"enrollment":100,"completionDate":"2029-08-31"},{"nctId":"NCT05667727","phase":"PHASE4","title":"The Effect of Nebulized Epinephrine in Asthma Exacerbation in Pediatric Age Group With the Standard Treatment Compared to Standard Treatment Using Improvement PRAM Score as a Primary Outcome","status":"COMPLETED","sponsor":"Oman Medical Speciality Board","startDate":"2023-10-15","conditions":["Shortness of Breath","Asthma in Children","Epinephrine Causing Adverse Effects in Therapeutic Use","Salbutamol Adverse Reaction"],"enrollment":30,"completionDate":"2025-06-01"},{"nctId":"NCT05786950","phase":"NA","title":"Neural Respiratory Drive of Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"The First Affiliated Hospital of Guangzhou Medical University","startDate":"2023-01-01","conditions":["Chronic Obstructive Pulmonary Disease"],"enrollment":44,"completionDate":"2024-09-01"},{"nctId":"NCT06074185","phase":"PHASE2","title":"Treating Respiratory Emergencies in Children Study","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2024-02-19","conditions":["Asthma in Children"],"enrollment":44,"completionDate":"2025-03-11"},{"nctId":"NCT06918418","phase":"PHASE4","title":"A Comparative Study of Adding Ipratropium to Salbutamol for the Treatment of Asthma Attack in Children","status":"COMPLETED","sponsor":"Children's Hospital and Institute of Child Health, Multan","startDate":"2024-01-01","conditions":["Asthma Exacerbation","Children"],"enrollment":60,"completionDate":"2024-07-15"},{"nctId":"NCT06825013","phase":"PHASE4","title":"Bronchodilators and Lung Mechanics During Exercise in COPD","status":"RECRUITING","sponsor":"Dr. J. Alberto Neder","startDate":"2024-11-10","conditions":["COPD"],"enrollment":25,"completionDate":"2027-01"},{"nctId":"NCT06657079","phase":"PHASE1,PHASE2","title":"A Combination of an Inhaled Budesonide and Ipratropium in Patients at Risk of Developing ARDS","status":"COMPLETED","sponsor":"Damanhour University","startDate":"2024-05-01","conditions":["ARDS","Prevention and Control"],"enrollment":119,"completionDate":"2025-01-01"},{"nctId":"NCT02755714","phase":"PHASE1,PHASE2","title":"Atrovent in Exercise Induced Laryngeal Obstruction (EILO)","status":"COMPLETED","sponsor":"Haukeland University Hospital","startDate":"2016-06-22","conditions":["Exercise Induced Laryngeal Obstruction (EILO)"],"enrollment":20,"completionDate":"2020-10-31"},{"nctId":"NCT00092989","phase":"PHASE3","title":"Investigation of Intravenous (IV) Administration of an Approved Drug (MK-0476, Montelukast Sodium) for Acute Asthma (MK-0476-288)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-07","conditions":["Asthma"],"enrollment":650,"completionDate":"2007-03"},{"nctId":"NCT06376942","phase":"PHASE2,PHASE3","title":"A RCT to Compare the Effectiveness of Nebulized Anticholinergics for Cough Suppression During Flexible Bronchoscopy","status":"NOT_YET_RECRUITING","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2024-04-24","conditions":["Subjects Undergoing Flexible Bronchoscopy"],"enrollment":1050,"completionDate":"2025-06-15"},{"nctId":"NCT03405090","phase":"PHASE4","title":"Differential Mechanisms of Dyspnea Relief in Advanced COPD: Opiates vs. Bronchodilators","status":"COMPLETED","sponsor":"Dr. Denis O'Donnell","startDate":"2017-09-20","conditions":["Chronic Obstructive Pulmonary Disease"],"enrollment":20,"completionDate":"2023-03-31"},{"nctId":"NCT06291740","phase":"NA","title":"Continuous Versus Intermittent Nebulization Therapy in Acute Asthma Exacerbation at Emergency Department","status":"UNKNOWN","sponsor":"Thammasat University","startDate":"2024-04","conditions":["Asthma Exacerbation","Emergency Department","Nebulization"],"enrollment":40,"completionDate":"2025-05"},{"nctId":"NCT05550402","phase":"NA","title":"Role of Parasympathetic Activity in Mild to Severe Asthma With Fixed Airway Obstruction (PARASMA Study)","status":"UNKNOWN","sponsor":"Hat Yai Medical Education Center","startDate":"2024-02-17","conditions":["Asthma","Airway Obstruction","Airway Remodeling","Parasympathetic Nervous System Diseases"],"enrollment":60,"completionDate":"2024-06-30"},{"nctId":"NCT06211920","phase":"NA","title":"Prehospital Non-invasive Ventilation for Acute Exacerbation of Chronic Obstructive Pulmonary Disease","status":"UNKNOWN","sponsor":"Central Denmark Region","startDate":"2023-12-08","conditions":["COPD Exacerbation","COPD Exacerbation Acute","Noninvasive Ventilation","Emergency Medical Services"],"enrollment":140,"completionDate":"2025-01-30"},{"nctId":"NCT05183841","phase":"NA","title":"Bronchodilators on the Exercise Capacity of Bronchiectasis Patients","status":"UNKNOWN","sponsor":"University of Sao Paulo General Hospital","startDate":"2022-04-14","conditions":["Bronchiectasis Adult"],"enrollment":40,"completionDate":"2025-11"},{"nctId":"NCT04617015","phase":"EARLY_PHASE1","title":"Defining and Treating Depression-related Asthma","status":"COMPLETED","sponsor":"State University of New York at Buffalo","startDate":"2016-09-09","conditions":["Asthma","Depression","Childhood Asthma"],"enrollment":40,"completionDate":"2019-03-11"},{"nctId":"NCT00388882","phase":"PHASE4","title":"Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent® Inhalation Aerosol in COPD Patients.","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-10-04","conditions":["Pulmonary Disease, Chronic Obstructive"],"enrollment":327,"completionDate":""},{"nctId":"NCT00576069","phase":"","title":"Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma","status":"RECRUITING","sponsor":"Gelb, Arthur F., M.D.","startDate":"2007-10-25","conditions":["Asthma"],"enrollment":60,"completionDate":"2027-06"},{"nctId":"NCT06040424","phase":"PHASE3","title":"Comparison of Ipratropium / Levosalbutamol Fixed Dose Combination and Ipratropium and Levosalbutamol Free Dose Combination in pMDI Form in Stable Chronic Obstructive Pulmonary Disease (COPD) Patients","status":"UNKNOWN","sponsor":"Neutec Ar-Ge San ve Tic A.Ş","startDate":"2023-09-28","conditions":["COPD"],"enrollment":74,"completionDate":"2024-06"},{"nctId":"NCT03157102","phase":"NA","title":"High Flow Nasal Cannula in Children With Status Asthmaticus","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2018-08-08","conditions":["Status Asthmaticus"],"enrollment":272,"completionDate":"2023-06-29"},{"nctId":"NCT05890638","phase":"PHASE3","title":"Comparison of Ipratropium / Levosalbutamol Fixed Dose Combination and Ipratropium and Levosalbutamol Free Dose Combination Nebuliser Solutions in Stable Chronic Obstructive Pulmonary Disease (COPD) Patients","status":"UNKNOWN","sponsor":"Neutec Ar-Ge San ve Tic A.Ş","startDate":"2023-08-25","conditions":["COPD"],"enrollment":74,"completionDate":"2024-03-06"},{"nctId":"NCT03029156","phase":"NA","title":"Effectiveness of the Aeroneb in Acute Severe Asthma","status":"COMPLETED","sponsor":"Tufts Medical Center","startDate":"2015-08","conditions":["Asthma Exacerbation"],"enrollment":31,"completionDate":"2019-08-01"},{"nctId":"NCT04503460","phase":"PHASE4","title":"Mechanisms of Adverse Effects of Long-Acting Beta-Agonists in Asthma","status":"UNKNOWN","sponsor":"Imperial College London","startDate":"2021-07-23","conditions":["Asthma"],"enrollment":24,"completionDate":"2024-09-30"},{"nctId":"NCT00521222","phase":"NA","title":"Evaluating Long Acting Beta Agonists Used to Treat Asthma Among Those With Either Arg/Arg or Gly/Gly Genotypes","status":"COMPLETED","sponsor":"Columbia University","startDate":"2007-06","conditions":["Asthma"],"enrollment":90,"completionDate":"2010-11"},{"nctId":"NCT03219736","phase":"NA","title":"NiPPV in the Treatment of Acute Asthma Exacerbations","status":"WITHDRAWN","sponsor":"Arkansas Children's Hospital Research Institute","startDate":"2017-06-01","conditions":["Bronchial Asthma","Status Asthmaticus"],"enrollment":0,"completionDate":"2019-01-01"},{"nctId":"NCT04655170","phase":"PHASE4","title":"Feasibility, Safety and Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Hospitalized Patients With AECOPD","status":"UNKNOWN","sponsor":"University of Tennessee Graduate School of Medicine","startDate":"2020-12-09","conditions":["COPD Exacerbation"],"enrollment":60,"completionDate":"2023-03-30"},{"nctId":"NCT03738917","phase":"PHASE4","title":"Effectiveness of Antitussives, Anticholinergics and Honey Versus Usual Care in Adults With Acute Bronchitis.","status":"COMPLETED","sponsor":"Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina","startDate":"2019-02-01","conditions":["Acute Bronchitis"],"enrollment":668,"completionDate":"2021-12-31"},{"nctId":"NCT00583778","phase":"NA","title":"A Comparison of Levalbuterol Plus Ipratropium With Levalbuterol Alone in the Treatment of Acute Asthma Exacerbation","status":"COMPLETED","sponsor":"MetroHealth Medical Center","startDate":"2004-08","conditions":["Asthma"],"enrollment":141,"completionDate":"2008-12"},{"nctId":"NCT04142814","phase":"NA","title":"Randomized Controlled Study on T-PEP Versus IPV Method for Lower Respiratory Airways Clearance in Tetraplegic Tracheotomized Spinal Cord Injured Patients","status":"WITHDRAWN","sponsor":"Montecatone Rehabilitation Institute S.p.A.","startDate":"2022-02","conditions":["Spinal Cord Injury Cervical"],"enrollment":0,"completionDate":"2023-08"},{"nctId":"NCT03064113","phase":"PHASE2","title":"Effects of TD-4208 on FEV1 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Mylan Inc.","startDate":"2011-05","conditions":["Chronic Obstructive Pulmonary Disease, COPD"],"enrollment":32,"completionDate":"2011-10"},{"nctId":"NCT02315144","phase":"PHASE1","title":"An Efficacy and Safety Profile of Inhaled TV48108 in Healthy Volunteers and COPD Patients","status":"TERMINATED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2015-04","conditions":["Chronic Obstructive Pulmonary Disease"],"enrollment":61,"completionDate":"2015-08"},{"nctId":"NCT02315131","phase":"PHASE1","title":"Study in Healthy Volunteers and COPD Patients to Evaluate the Efficacy and Safety of Inhaled TV46017","status":"TERMINATED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2015-03","conditions":["Chronic Obstructive Pulmonary Disease (COPD"],"enrollment":53,"completionDate":"2015-08"},{"nctId":"NCT03051971","phase":"NA","title":"Medicated Aerosol Delivery Using A Jet Nebulizer Versus A Vibrating Mesh Nebulizer in COPD Exacerbation","status":"WITHDRAWN","sponsor":"Medstar Health Research Institute","startDate":"2017-03","conditions":["Chronic Obstructive Pulmonary Disease"],"enrollment":0,"completionDate":"2018-04"},{"nctId":"NCT00674817","phase":"PHASE2","title":"An Investigation Of The Interaction Of GSK961081 With Inhaled Beta-Agonist And Anti-Muscarinic Drugs.","status":"COMPLETED","sponsor":"Theravance Biopharma","startDate":"2008-04-01","conditions":["Pulmonary Disease, Chronic Obstructive"],"enrollment":45,"completionDate":"2008-10-19"},{"nctId":"NCT04446637","phase":"PHASE3","title":"Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD","status":"WITHDRAWN","sponsor":"Neutec Ar-Ge San ve Tic A.Ş","startDate":"2021-09-03","conditions":["Chronic Obstructive Pulmonary Disease"],"enrollment":0,"completionDate":"2022-09-03"},{"nctId":"NCT03219866","phase":"PHASE4","title":"Nebulizer Versus Dry Powdered Inhalers for Chronic Obstructive Pulmonary Disease (COPD)","status":"TERMINATED","sponsor":"Wake Forest University Health Sciences","startDate":"2017-10-03","conditions":["COPD","COPD Exacerbation"],"enrollment":40,"completionDate":"2020-04-01"},{"nctId":"NCT01253473","phase":"PHASE4","title":"Symbicort in Airway Predominant Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"National Jewish Health","startDate":"2012-04","conditions":["Pulmonary Disease, Chronic Obstructive"],"enrollment":46,"completionDate":"2016-01"},{"nctId":"NCT01045174","phase":"NA","title":"Breath-Actuated Nebulizer Versus Conventional Continuous-Output Nebulizer in Pediatric Asthma Patients","status":"TERMINATED","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2008-12","conditions":["Asthma"],"enrollment":180,"completionDate":"2010-12"},{"nctId":"NCT02458482","phase":"NA","title":"Trial of AccuPAP Device Versus Standard Nebulizer Therapy in Acute Asthma Exacerbation in Children","status":"WITHDRAWN","sponsor":"Vanderbilt University Medical Center","startDate":"2015-07","conditions":["Asthma"],"enrollment":0,"completionDate":"2020-11-11"},{"nctId":"NCT00522444","phase":"PHASE3","title":"Nebulized Magnesium Sulfate in Pediatric Asthma","status":"WITHDRAWN","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2007-09","conditions":["Asthma"],"enrollment":0,"completionDate":"2013-09"},{"nctId":"NCT03170232","phase":"PHASE2","title":"A Pilot Study of Danirixin for Disease Progression in Chronic Obstructive Pulmonary Disease (COPD)","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2017-10-16","conditions":["Pulmonary Disease, Chronic Obstructive"],"enrollment":54,"completionDate":"2018-11-15"},{"nctId":"NCT01691079","phase":"PHASE4","title":"Effectiveness of Ipratropium Bromide in Preventing Exercise-induced Bronchoconstriction in Athletes","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2012-12","conditions":["Bronchospasm, Exercise-Induced"],"enrollment":20,"completionDate":"2014-12"},{"nctId":"NCT04181073","phase":"NA","title":"Borg Score Outcomes in Respiratory Compromised Acute Exacerbating Chronic Obstructive Pulmonary Disease (COPD) Patients Receiving Treatment Via Vibrating Mesh Nebuliser Versus Jet Nebuliser in the Emergency Department","status":"UNKNOWN","sponsor":"NHS Greater Clyde and Glasgow","startDate":"2019-07-01","conditions":["COPD Exacerbation","COPD"],"enrollment":150,"completionDate":"2021-10"},{"nctId":"NCT04167280","phase":"PHASE4","title":"Regular Use Effect of Inhaled Ipratropium Bromide on Airway Responsiveness to Methacholine in Well-controlled Asthma","status":"COMPLETED","sponsor":"University of Saskatchewan","startDate":"2019-11-05","conditions":["Asthma"],"enrollment":12,"completionDate":"2020-03-13"},{"nctId":"NCT02782052","phase":"PHASE3","title":"Bronchodilator's Effects on Exertional Dyspnoea in Pulmonary Arterial Hypertension","status":"WITHDRAWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2016-07","conditions":["Pulmonary Arterial Hypertension"],"enrollment":0,"completionDate":"2019-02"},{"nctId":"NCT02509299","phase":"NA","title":"Effect of Physiotherapy in Hospitalized COPD Patients","status":"COMPLETED","sponsor":"Universidad de Granada","startDate":"2019-09-01","conditions":["COPD"],"enrollment":49,"completionDate":"2019-12-14"},{"nctId":"NCT03031093","phase":"NA","title":"Aerosol Therapy in Obese COPD Patients.","status":"COMPLETED","sponsor":"Universidade Federal do Rio Grande do Norte","startDate":"2017-12-02","conditions":["Chronic Obstructive Pulmonary Disease Moderate","Obesity"],"enrollment":50,"completionDate":"2018-05-05"},{"nctId":"NCT04101500","phase":"PHASE4","title":"Effect of Compound Sodium Chlorate and Aminophylline Tablets on Chronic Obstructive Pulmonary Disease(COPD).","status":"UNKNOWN","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2019-04-01","conditions":["Acute Exacerbation of Chronic Obstructive Pulmonary Disease"],"enrollment":200,"completionDate":"2024-12-30"},{"nctId":"NCT00624650","phase":"PHASE2","title":"Hemodynamics and Extravascular Lung Water in Acute Lung Injury","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2008-02","conditions":["Acute Lung Injury"],"enrollment":33,"completionDate":"2011-01"},{"nctId":"NCT02686086","phase":"NA","title":"A Pilot Comparison Study of Vibrating Mesh Versus Standard Jet Nebuliser for Bronchodilator Delivery in COPD","status":"COMPLETED","sponsor":"Beaumont Hospital","startDate":"2016-02","conditions":["Chronic Obstructive Pulmonary Disease (COPD)"],"enrollment":60,"completionDate":"2017-07"},{"nctId":"NCT03286855","phase":"NA","title":"Effectiveness of Vibrating Mesh Versus Small Volume Nebuliser in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Beaumont Hospital","startDate":"2017-10-18","conditions":["Chronic Obstructive Pulmonary Disease","COPD","Copd Exacerbation Acute","COPD Exacerbation"],"enrollment":62,"completionDate":"2018-09-30"},{"nctId":"NCT04016220","phase":"PHASE1","title":"Nebulized Budesonide Combined With Systemic Corticosteroid in Acute Severe Asthma","status":"UNKNOWN","sponsor":"University of Monastir","startDate":"2019-05-20","conditions":["Acute Asthma"],"enrollment":60,"completionDate":"2020-05-20"},{"nctId":"NCT01415518","phase":"PHASE4","title":"Efficacy and Tolerability Study in Severe Chronic Obstructive Pulmonary Disease (COPD) Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-09-01","conditions":["Chronic Obstructive Pulmonary Disease (COPD)"],"enrollment":581,"completionDate":"2012-12-01"},{"nctId":"NCT03271905","phase":"NA","title":"Influence of Mechanical Ventilation Modes on the Efficacy of Nebulized Bronchodilator","status":"UNKNOWN","sponsor":"Universidade Federal do Rio Grande do Norte","startDate":"2017-04-10","conditions":["COPD","Asthma"],"enrollment":10,"completionDate":"2019-12-10"},{"nctId":"NCT02872597","phase":"PHASE1","title":"Phase I, Placebo-Controlled, Blinded Pilot Study of Ipratropium in Children Admitted to the ICU With Status Asthmaticus","status":"COMPLETED","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2016-09-05","conditions":["Status Asthmaticus"],"enrollment":30,"completionDate":"2018-08-16"},{"nctId":"NCT01070225","phase":"PHASE4","title":"Reversal of Acute β-Blocker Induced Bronchoconstriction","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2010-03","conditions":["Asthma"],"enrollment":14,"completionDate":"2010-10"},{"nctId":"NCT03136120","phase":"","title":"Cryobiopsy Study to Assess Drug Distribution in Subjects With Suspected Interstitial Lung Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-11-21","conditions":["Lung Diseases, Interstitial"],"enrollment":8,"completionDate":"2018-11-13"},{"nctId":"NCT01696214","phase":"PHASE4","title":"A Pilot Study to Determine the Feasibility and Utility of Implementing of the Full Scale TOM Trial","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2012-10","conditions":["Asthma"],"enrollment":20,"completionDate":"2016-11"},{"nctId":"NCT03747536","phase":"PHASE2","title":"Ipratropium Bromide Spray as Treatment for Sialorrhea in Children","status":"UNKNOWN","sponsor":"London Health Sciences Centre","startDate":"2019-01-01","conditions":["Sialorrhea"],"enrollment":30,"completionDate":"2021-01-01"},{"nctId":"NCT02172443","phase":"PHASE3","title":"Comparison of Tiotropium Inhalation Capsules and Atrovent Metered Dose Inhaler (MDI) in a Efficacy and Safety Study in Adults With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2001-06","conditions":["Pulmonary Disease, Chronic Obstructive"],"enrollment":50,"completionDate":""},{"nctId":"NCT02172404","phase":"PHASE3","title":"HandiHaler® vs. Metered Dose Inhaler (MDI) in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2000-10","conditions":["Pulmonary Disease, Chronic Obstructive"],"enrollment":160,"completionDate":""},{"nctId":"NCT02182674","phase":"PHASE2","title":"A Confirmation Study of Combivent HFA Inhalation Aerosol in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2000-10","conditions":["Pulmonary Disease, Chronic Obstructive"],"enrollment":66,"completionDate":""},{"nctId":"NCT02515318","phase":"NA","title":"Physiotherapy in Acute Exacerbation of Chronic Obstructive Pulmonary Disease","status":"UNKNOWN","sponsor":"Universidad de Granada","startDate":"2015-09","conditions":["COPD"],"enrollment":60,"completionDate":"2018-07"},{"nctId":"NCT03071731","phase":"NA","title":"Glittre ADL-test: Responsiveness to Acute Bronchodilation in Chronic Obstructive Pulmonary Disease (COPD)","status":"UNKNOWN","sponsor":"Laval University","startDate":"2017-04-13","conditions":["Chronic Obstructive Pulmonary Disease"],"enrollment":34,"completionDate":"2019-06-15"},{"nctId":"NCT01350128","phase":"PHASE2","title":"PT001 MDI Versus Atrovent Study in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2011-05-01","conditions":["Chronic Obstructive Pulmonary Disease"],"enrollment":103,"completionDate":"2011-10-01"},{"nctId":"NCT01691482","phase":"PHASE4","title":"A Study to Look at Day to Day Changes in Lung Function in COPD Subjects Taking Albuterol/Salbutamol and Ipratropium","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-07-23","conditions":["Pulmonary Disease, Chronic Obstructive"],"enrollment":56,"completionDate":"2012-10-22"},{"nctId":"NCT03062904","phase":"NA","title":"Search of a Paradoxical Fall in Maximum Expiratory Flow After Bronchodilation in Healthy Subjects","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2014-02","conditions":["Paradoxical Fall in Maximum Expiratory Flows"],"enrollment":65,"completionDate":"2019-12"},{"nctId":"NCT01426009","phase":"PHASE2","title":"Study to Investigate the Dose Response, Safety and Efficacy of Nebulized EP-101(SUN101) in Patients With Chronic Obstructive Pulmonary Disease (COPD): GOLDEN-1 Study","status":"COMPLETED","sponsor":"Sunovion Respiratory Development Inc.","startDate":"2011-08","conditions":["Chronic Obstructive Pulmonary Disease"],"enrollment":140,"completionDate":"2011-12"},{"nctId":"NCT03296579","phase":"NA","title":"Non-invasive Ventilation vs. Standard Therapy for Children Hospitalized With an Acute Exacerbation of Asthma","status":"UNKNOWN","sponsor":"University of British Columbia","startDate":"2018-06","conditions":["Asthma Acute","Asthma in Children"],"enrollment":100,"completionDate":"2018-12"},{"nctId":"NCT03480997","phase":"PHASE1","title":"Acute Bronchodilator Effect of Inhaled Albuterol Sulfate and Ipratropium Bromide in Patients With Stable COPD","status":"COMPLETED","sponsor":"Pneuma Respiratory, Inc","startDate":"2016-12-27","conditions":["COPD"],"enrollment":46,"completionDate":"2017-04-28"},{"nctId":"NCT00584181","phase":"","title":"High-resolution Computed Tomography (HRCT) Evaluation of Airway Distensibility in Lung Transplant Recipients","status":"COMPLETED","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2007-08","conditions":["Unspecified Complication of Lung Transplant"],"enrollment":10,"completionDate":"2018-01-07"},{"nctId":"NCT00708227","phase":"","title":"Pharmacogenetics of b2-Agonists in Asthma.","status":"COMPLETED","sponsor":"Nemours Children's Clinic","startDate":"2007-09","conditions":["Asthma"],"enrollment":88,"completionDate":"2012-08"},{"nctId":"NCT00296946","phase":"PHASE2","title":"Ipratropium Spray for Drooling Saliva in Parkinson's Disease","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2004-11","conditions":["Parkinson's Disease"],"enrollment":20,"completionDate":"2006-06"},{"nctId":"NCT01944033","phase":"PHASE3","title":"β2-agonist Versus Ipratropium Bromide Associated With β2-agonists in Chronic Obstructive Pulmonary Disease Exacerbation","status":"COMPLETED","sponsor":"University of Monastir","startDate":"2013-07","conditions":["Acute Exacerbation of Chronic Obstructive Airways Disease"],"enrollment":250,"completionDate":"2017-01"},{"nctId":"NCT02576626","phase":"PHASE4","title":"Single Dose Ultibro Breezhaler by Sd-DPI Versus Ipratropium/Salbutamol by Nebulizer in COPD","status":"COMPLETED","sponsor":"Wouter H. van Geffen","startDate":"2015-12","conditions":["COPD"],"enrollment":40,"completionDate":"2017-09-29"},{"nctId":"NCT00549120","phase":"PHASE1","title":"Optimising the Propranolol Block Model","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-08-15","conditions":["Pulmonary Disease, Chronic Obstructive"],"enrollment":18,"completionDate":"2007-10-26"},{"nctId":"NCT01331694","phase":"","title":"Outcomes and Costs Associated With Initiating Maintenance Treatment With Fluticasone Propionate 250mcg/Salmeterol Xinafoate 50mcg Combination (FSC) Versus Anticholinergics Including Tiotropium (TIO) in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-07","conditions":["Pulmonary Disease, Chronic Obstructive"],"enrollment":76130,"completionDate":"2010-05"},{"nctId":"NCT02207452","phase":"PHASE1","title":"Helium-3 MRI Imaging Study in COPD","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-08-05","conditions":["Pulmonary Disease, Chronic Obstructive"],"enrollment":11,"completionDate":"2011-07-04"},{"nctId":"NCT01332461","phase":"","title":"Chronic Obstructive Pulmonary Disease (COPD)-Related Healthcare Utilization and Costs After Discharge From a Hospitalization or Emergency Department Visit on a Regimen of Fluticasone Propionate-Salmeterol Combination Versus Other Maintenance Therapies","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-11","conditions":["Pulmonary Disease, Chronic Obstructive"],"enrollment":5677,"completionDate":"2010-05"},{"nctId":"NCT01337336","phase":"","title":"Chronic Obstructive Pulmonary Disease (COPD)-Related Outcomes and Costs for Patients on Combination Fluticasone Propionate-Salmeterol Xinafoate 250/50mcg Versus Anticholinergics in a COPD-Comorbid Depression/Anxiety Population","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-10","conditions":["Pulmonary Disease, Chronic Obstructive"],"enrollment":1,"completionDate":"2011-03"},{"nctId":"NCT01381458","phase":"","title":"Risk of Re-Hospitalization in Patients With Chronic Obstructive Pulmonary Disease (COPD) Post Exacerbation","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-09","conditions":["Pulmonary Disease, Chronic Obstructive"],"enrollment":1936,"completionDate":"2011-03"},{"nctId":"NCT01395875","phase":"","title":"Outcomes for Chronic Obstructive Pulmonary Disease Moderate Exacerbators Initiating Treatment","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-03","conditions":["Pulmonary Disease, Chronic Obstructive"],"enrollment":2849,"completionDate":"2011-06"},{"nctId":"NCT03042065","phase":"NA","title":"Salbutamol in the Pediatric Emergencies: Nebulization Estimated Via AerogeN or Jet","status":"UNKNOWN","sponsor":"Centre d'Investigation Clinique et Technologique 805","startDate":"2017-03","conditions":["Asthma"],"enrollment":60,"completionDate":"2017-09"},{"nctId":"NCT03038295","phase":"PHASE2","title":"a Prospective Cohort Study for Propranolol Treatment in Retinopathy of Prematurity","status":"UNKNOWN","sponsor":"Guangdong Women and Children Hospital","startDate":"2017-03","conditions":["Retinopathy of Prematurity"],"enrollment":100,"completionDate":"2019-12"},{"nctId":"NCT02790047","phase":"NA","title":"Effect of Home-base Exercise With Conical-PEP Device on Physical Performance and Quality of Life in COPD","status":"UNKNOWN","sponsor":"Khon Kaen University","startDate":"2016-10","conditions":["Chronic Obstructive Pulmonary Disease"],"enrollment":50,"completionDate":"2018-05"},{"nctId":"NCT01943552","phase":"PHASE4","title":"Ipratropium Bromide in Peri-Operative COPD","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2013-10","conditions":["Pulmonary Disease, Chronic Obstructive"],"enrollment":192,"completionDate":"2015-08"},{"nctId":"NCT02542254","phase":"PHASE2","title":"The Effects of RPL554 on Top of Standard COPD Reliever Medications","status":"COMPLETED","sponsor":"Verona Pharma plc","startDate":"2015-10","conditions":["Chronic Obstructive Pulmonary Disease"],"enrollment":36,"completionDate":"2015-12"},{"nctId":"NCT01987219","phase":"PHASE3","title":"The Effects Of Bronchodilator Therapy On Respiratory And Autonomic Function In Patients With Familial Dysautonomia","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2013-03","conditions":["Familial Dysautonomia"],"enrollment":15,"completionDate":"2014-12"},{"nctId":"NCT02103374","phase":"PHASE4","title":"Evaluation of Benefit of Nebulized Bronchodilators at Home in Severe Chronic Obstructive Pulmonary Disease and Very Severe Steady State","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2012-01","conditions":["Severe Chronic Obstructive Pulmonary Disease"],"enrollment":45,"completionDate":"2015-12"},{"nctId":"NCT00117182","phase":"PHASE2","title":"Aridol Challenge as a Tool to Predict Treatment Response to Inhaled Corticosteroids in COPD","status":"COMPLETED","sponsor":"Syntara","startDate":"2005-07","conditions":["Lung Diseases, Obstructive"],"enrollment":140,"completionDate":"2006-08"},{"nctId":"NCT00000568","phase":"PHASE3","title":"Lung Health Study (LHS) I and III","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1984-09","conditions":["Lung Diseases","Lung Diseases, Obstructive","Chronic Obstructive Pulmonary Disease"],"enrollment":0,"completionDate":"2005-01"},{"nctId":"NCT00588406","phase":"PHASE3","title":"Study of Budesonide as an Addition to Standard Therapy in Adult Asthmatics in the Emergency Room.","status":"COMPLETED","sponsor":"Northwell Health","startDate":"2007-09","conditions":["Asthma"],"enrollment":95,"completionDate":"2009-12"},{"nctId":"NCT02584738","phase":"PHASE4","title":"Nebulized Magnesium Sulfate as an Adjunct to Standard Therapy in Asthma Exacerbation","status":"UNKNOWN","sponsor":"Hospital General Naval de Alta Especialidad - Escuela Medico Naval","startDate":"2015-09","conditions":["Asthma"],"enrollment":152,"completionDate":"2018-01"},{"nctId":"NCT01151579","phase":"PHASE4","title":"Effect of Nebulized Bronchodilators on Heart Rate","status":"COMPLETED","sponsor":"Fahim Khorfan, MD","startDate":"2008-12","conditions":["COPD","Sepsis","Shock"],"enrollment":89,"completionDate":"2009-11"},{"nctId":"NCT02296047","phase":"NA","title":"Ventilation-drive Coupling to Evaluate The Efficacy of Inhaled Bronchodilators in Patients With COPD","status":"COMPLETED","sponsor":"Zhujiang Hospital","startDate":"2014-12","conditions":["Chronic Obstructive Pulmonary Disease (COPD)"],"enrollment":22,"completionDate":"2015-05"},{"nctId":"NCT02504801","phase":"PHASE4","title":"Efficacy of Nebulized Pulmicort Respules in Primary Lung Cancer Patients With COPD","status":"UNKNOWN","sponsor":"Xiuyi Zhi","startDate":"2015-07","conditions":["Post Operative Complication, Pulmonary","Lung Cancer","COPD"],"enrollment":73,"completionDate":"2016-10"}],"whoEssential":true,"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Nasal","formulation":"Aerosol, Inhalant, Solution, Spray","formulations":[{"form":"AEROSOL, METERED","route":"RESPIRATORY (INHALATION)","productName":"Atrovent HFA"},{"form":"AEROSOL, METERED","route":"RESPIRATORY (INHALATION)","productName":"AtroventHFA"},{"form":"INHALANT","route":"RESPIRATORY (INHALATION)","productName":"Ipratropium Bromide and Albuterol Sulfate"},{"form":"SOLUTION","route":"RESPIRATORY (INHALATION)","productName":"IPRATROPIUM BROMIDE AND ALBUTEROL SULFATE"},{"form":"SOLUTION","route":"RESPIRATORY (INHALATION)","productName":"Ipratropium Bromide"},{"form":"SOLUTION","route":"RESPIRATORY (INHALATION)","productName":"Ipratropium Bromide and Albuterol Sulfate"},{"form":"SOLUTION","route":"RESPIRATORY (INHALATION)","productName":"Ipratropium bromide"},{"form":"SOLUTION","route":"RESPIRATORY (INHALATION)","productName":"ipratropium bromide and albuterol sulfate"},{"form":"SOLUTION","route":"RESPIRATORY (INHALATION)","productName":"Ipratropium Bromide and Albuterol Sulfate"},{"form":"SPRAY","route":"NASAL","productName":"Ipratropium Bromide"},{"form":"SPRAY, METERED","route":"NASAL","productName":"Ipratropium Bromide"},{"form":"SPRAY, METERED","route":"NASAL","productName":"Ipratropium bromide"},{"form":"SPRAY, METERED","route":"NASAL","productName":"Atrovent"},{"form":"SPRAY, METERED","route":"RESPIRATORY (INHALATION)","productName":"Combivent Respimat"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000147880","MMSL":"4916","NDDF":"001750","UNII":"GR88G0I6UL","VUID":"4019791","CHEBI":"CHEBI:5956","VANDF":"4019341","RXNORM":"1309404","UMLSCUI":"C0027235","chemblId":"CHEMBL1621597","ChEMBL_ID":"CHEMBL1621597","KEGG_DRUG":"D02212","DRUGBANK_ID":"DB00332","PDB_CHEM_ID":" X8M","PUBCHEM_CID":"3746","SNOMEDCT_US":"108624006","IUPHAR_LIGAND_ID":"325","SECONDARY_CAS_RN":"66985-17-9","MESH_DESCRIPTOR_UI":"D009241"},"formularyStatus":[],"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"present","companyName":"Boehringer Ingelheim","relationship":"Current Owner"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"1.64 hours","clearance":"31.4 mL/min/kg","bioavailability":"3%","fractionUnbound":"0.95%","volumeOfDistribution":"5.1 L/kg"},"publicationCount":2235,"therapeuticAreas":["Neuroscience"],"atcClassification":{"source":"DrugCentral","atcCode":"R01AX03","allCodes":["R01AX03","R03AL01","R03AL02","R03BB01"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar 25","pmid":"41837861","title":"The usefulness of the new SOBIstat-F(®) device in children with severe acute asthma attacks in the emergency department: a randomized clinical trial.","journal":"The Journal of asthma : official journal of the Association for the Care of Asthma"},{"date":"2026","pmid":"41822328","title":"Pulmonary infection by Nocardia saintgeorgesii mimicking lung cancer with concurrent pulmonary embolism in an immunocompetent host: a case highlighting the diagnostic role of mNGS.","journal":"Frontiers in cellular and infection microbiology"},{"date":"2026 Feb 22","pmid":"41762556","title":"A rare case of lung hernia associated with rib fractures and tension pneumothorax post cardiopulmonary resuscitation.","journal":"The American journal of emergency medicine"},{"date":"2026 Feb 27","pmid":"41760017","title":"A case report of combined oxidative phosphorylation deficiency 35 (COXPD35) in Palestine caused by novel compound heterozygous TRIT1 variants.","journal":"Medicine"},{"date":"2026 Feb 19","pmid":"41714644","title":"Evaluation of artificial intelligence identified ipratropium bromide for the treatment of coronavirus disease 2019.","journal":"Scientific reports"}],"combinationProducts":[{"brandName":"Combivent Respimat","ingredients":"ipratropium + salbutamol"},{"brandName":"Ipratropium Bromide and Albuterol Sulfate","ingredients":"ipratropium + salbutamol"}],"companionDiagnostics":[],"genericManufacturers":19,"_genericFilersChecked":true,"genericManufacturerList":["Actavis Mid Atlantic","Amneal","Apotex Inc","Armstrong Pharms","Aurobindo Pharma Usa","Bausch","Hikma","Landela Pharm","Luoxin Aurovitas","Lupin","Nephron","Pharmobedient","Ritedose Corp","Roxane","Rubicon Research","Sun Pharm","Teva Pharms Usa","Watson Labs","Zennova"],"status":"approved","companyName":"Boehringer Ingelheim","companyId":"","modality":"Small molecule","firstApprovalDate":"1986","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1986-12-29T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2003-11-05T00:00:00.000Z","mah":"HIKMA","brand_name_local":null,"application_number":"ANDA076598"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2013-05-20T00:00:00.000Z","mah":"RITEDOSE CORP","brand_name_local":null,"application_number":"ANDA075693"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2016-10-27T00:00:00.000Z","mah":"LUOXIN AUROVITAS","brand_name_local":null,"application_number":"ANDA206543"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2020-07-09T00:00:00.000Z","mah":"LUOXIN AUROVITAS","brand_name_local":null,"application_number":"ANDA206532"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2026-02-23T00:00:00.000Z","mah":"ARMSTRONG PHARMS","brand_name_local":null,"application_number":"ANDA217953"},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:44:18.579608+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}